• U.S. Burden of Skin and Subcutaneous Diseases Increasing

    Healthday News Conditions, HealthDay News Physician's Briefing June 25, 2020
  • Can dermatology employers require employees to receive the COVID-19 vaccine?

    American Academy of Dermatology AAD, Conditions, Coronavirus, COVID-19 January 28, 2021
  • THE 2020 VISION FOR NEMOLIZUMAB IN ATOPIC DERMATITIS

    American Academy of Dermatology AAD, Atopic Dermatitis, Conditions, Dermatology January 26, 2021
  • Expression of retinoid receptors in hand eczema.

    ClinOwl Atopic Dermatitis, ClinOwl, Conditions, Eczema October 1, 2020
  • S. aureus Agr Virulence Tied to Atopic Dermatitis in Infants

    Healthday News Atopic Dermatitis, Conditions, Eczema July 28, 2020
  • Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces.

    ClinOwl ClinOwl, Conditions, COVID-19, Psoriasis July 26, 2020

DermConnect® is an official licensee of the American Academy of Dermatology.

DermConnect®
Navigation
  • Home
  • Atopic Dermatitis
  • Psoriasis
    • Chronic Plaque Psoriasis
    • Guttate Psoriasis
  • Skin Cancer
    • Basal Cell Carcinoma
    • Cutaneous T-cell Lymphoma
    • Dermatofibrosarcoma Protuberans (DFSP)
    • Melanoma
    • Merkel Cell Carcinoma
    • Sebaceous Carcinoma
    • Squamous Cell Carcinoma
  • Home
  • Atopic Dermatitis
  • Psoriasis
    • Chronic Plaque Psoriasis
    • Guttate Psoriasis
  • Skin Cancer
    • Basal Cell Carcinoma
    • Cutaneous T-cell Lymphoma
    • Dermatofibrosarcoma Protuberans (DFSP)
    • Melanoma
    • Merkel Cell Carcinoma
    • Sebaceous Carcinoma
    • Squamous Cell Carcinoma
Home Posts Dermatology

Category Archive

  • Dermatology / November 12, 2020

    Scoping the international impact from four independent national dermatology trials.

    View Post
  • Dermatology / January 22, 2021

    Bromhidrosis Treatment Modalities: A Literature Review.

    View Post
  • Dermatology / October 2, 2020

    Topical anti-microbial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild-to-moderate atopic dermatitis in a phase 2 randomized controlled trial.

    View Post
  • Dermatology / May 3, 2021

    Reporting of randomized controlled trial abstracts in dermatology journals according to CONSORT guidelines.

    View Post
  • Dermatology / September 28, 2020

    QuantiFERON TB-gold conversion rate among psoriasis patients under biologics: a 9-year retrospective study.

    View Post

Clinical Characteristics and Burden of Disease in Prurigo Nodularis.

In Dermatology
by ClinOwl
May 9, 2021

Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intense pruritus, but information on patient experience and impact on quality of life (QoL) remains understudied.To characterize disease characteristics …

Comorbidities, Mortality and Survival in Patients with Pyoderma Gangrenosum: A Danish Nationwide Registry-Nested Case-Control Study.

In Dermatology
by ClinOwl
May 9, 2021

Pyoderma gangrenosum (PG) is an ulcerative skin disease associated with comorbidities and increased mortality. However, the literature on this topic is scarce.To investigate the mortality, prevalence and risk of comorbidities …

Paternal and maternal use of dupilumab in patients with atopic dermatitis: a case series.

In Dermatology
by ClinOwl
May 9, 2021

Dupilumab is a relatively new treatment option for patients with moderate-to-severe atopic dermatitis. There is a lack of knowledge about treatment with dupilumab during conception in both males and females, …

International registry of dermatological manifestations secondary to COVID-19 infection in 347 Hispanic patients from 25 countries.

In Dermatology
by ClinOwl
May 7, 2021

The infection by coronavirus disease 2019 (COVID-19) has been associated with multiple cutaneous manifestations, although characterization of them in Hispanic patients with darker skin phototypes is lacking. The objective of …

A GWAS identifies novel gene associations with facial skin wrinkling and mole count in Latin-Americans.

In Dermatology
by ClinOwl
May 6, 2021

Genome-wide association studies (GWAS) have identified genes influencing skin ageing and mole count in Europeans but little is known about the relevance of these (or other genes) in non-Europeans.To conduct …

Domains and outcomes of the core outcome set of congenital melanocytic naevi for clinical practice and research, part 2 (the OCOMEN project).

In Dermatology
by ClinOwl
May 6, 2021

Congenital melanocytic naevi (CMN) can have a great impact on patients’ lives due to perceived stigmatization and the risk of melanoma development and neurological complications. Development of a core outcome …

Evaluation of plasma and urinary levels of vascular endothelial growth factor and matrix metalloproteinase-9 in patients with infantile hemangioma.

In Dermatology
by ClinOwl
May 6, 2021

The pathogenesis of infantile hemangioma (IH) is not fully understood. It has been suggested that angiogenic factors increase in the proliferative stage, decreasing subsequently in the regression phase.To evaluate vascular …

Systematic Review and Meta-Analysis of Local Recurrence Rates of Head and Neck Cutaneous Melanomas after Wide Local Excision, Mohs Micrographic Surgery, or Staged Excision.

In Dermatology
by ClinOwl
May 6, 2021

Prospective trials have not compared local recurrence rates for different excision techniques for cutaneous melanomas on the head and neck.To determine local recurrence rates of cutaneous head and neck melanoma …

Views on Mobile Health Apps for Skin Cancer Screening in the General Population: An In-Depth Qualitative Exploration of Perceived Barriers and Facilitators.

In Dermatology
by ClinOwl
May 6, 2021

Mobile health (mHealth) applications (apps) integrated with artificial Intelligence (AI) for skin cancer screening are increasingly reimbursed by health insurers. However, an in-depth exploration of the general public’s views towards …

Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies.

In Dermatology
by ClinOwl
May 5, 2021

Ruxolitinib (RUX) cream demonstrated potent anti-inflammatory and antipruritic efficacy in a phase 2 study in adults with atopic dermatitis (AD).To evaluate 8-week efficacy and safety in two phase 3 studies …

  • Page 9 of 57
  • ←
  • 1
  • ...
  • 8
  • 9
  • 10
  • ...
  • 57
  • →

TRENDING

  • Dose Range for Iberdomide Studied in Systemic Lupus Erythematosus
  • YouTube Video Quality for Aesthetic Injectables Lower Than Quality of Websites
  • Cardiac Biomarkers and CV Risk Examined in Psoriatic Disease
  • Lymph Node Dissection Declining in SLN-Positive Melanoma
  • Debt Valuation of Private Equity-Backed Dermatology Groups Down

About DermConnect®

DermConnect® curates the latest in dermatology news and resources from some of the most trusted and respected names in healthcare, including the American Academy of Dermatology, ClinOwl, HealthDay and Dermnet NZ.

LATEST ARTICLES

  • Dose Range for Iberdomide Studied in Systemic Lupus Erythematosus March 16, 2022
  • YouTube Video Quality for Aesthetic Injectables Lower Than Quality of Websites March 11, 2022
  • Cardiac Biomarkers and CV Risk Examined in Psoriatic Disease March 11, 2022
  • Lymph Node Dissection Declining in SLN-Positive Melanoma March 9, 2022
  • Debt Valuation of Private Equity-Backed Dermatology Groups Down March 9, 2022

Quick Links

  • Home
  • Atopic Dermatitis
  • Psoriasis
    • Chronic Plaque Psoriasis
    • Guttate Psoriasis
  • Skin Cancer
    • Basal Cell Carcinoma
    • Cutaneous T-cell Lymphoma
    • Dermatofibrosarcoma Protuberans (DFSP)
    • Melanoma
    • Merkel Cell Carcinoma
    • Sebaceous Carcinoma
    • Squamous Cell Carcinoma

About DermConnect®

DermConnect® curates the latest in dermatology news and resources from some of the most trusted and respected names in healthcare, including the American Academy of Dermatology, ClinOwl, HealthDay and Dermnet NZ.

SCHEDULE

June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
« Mar    

All content indicated on this website as authored by "AAD" is owned by and licensed with the permission of the American Academy of Dermatology (“AAD”) for personal educational use.

The content may not be distributed in whole or in part to any third parties without express written permission from AAD,
nor may viewers of this site translate, edit, modify or otherwise create derivative works from the content.

The licensing of the content by AAD does not constitute or imply any endorsement of any company and/or any of its goods, services or written work product.

 

  • Home
  • Atopic Dermatitis
  • Psoriasis
  • Skin Cancer